PROGRAM DESCRIPTION
Despite the disability and socioeconomic burden associated with migraine, underdiagnosis and undertreatment remain significant problems in clinical practice, and effective treatment can be elusive. Triptans—the longtime cornerstone of acute treatment—are ineffective, poorly tolerated, or contradicted in many patients, leading to low rates of use and high rates of discontinuation, with recent data suggesting that less than one-fourth of patients currently use prescription medication for acute migraine relief. Poor or inadequate acute migraine treatment can result in progression from episodic to chronic migraine or medication overuse headache.

While new approaches to migraine prophylaxis have understandably generated great excitement, equally important developments in acute migraine treatment have also emerged recently. Growing understanding of migraine pathophysiology has spurred the development of novel targeted therapies, including 5-HT1F receptor agonists and calcitonin gene-related peptide receptor agonists, drug classes that are free of the cardiovascular contraindications of older migraine medications. Triptans, too, have evolved, with delivery modifications that can improve bioavailability, speed of onset, and tolerability.

Family physicians and other primary care providers on the frontline of migraine care need to learn about the role that new and emerging treatments can play in optimizing clinical care for patients with migraine.

FACULTY CO-CHAIRS
Susan Hutchinson, MD
Director
Orange County Migraine & Headache Center
Irvine, CA

Stewart J. Tepper, MD, FAHS
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, NH

LEARNING OBJECTIVES
After participating in this activity, learners should be better able to:
- Appreciate the prevalence of migraine in a primary care setting
- Utilize established criteria to make differential diagnoses for migraine headache and to distinguish episodic from chronic migraine
- Assess the evidence regarding the potential benefits and risks of emerging acute migraine treatments

INTENDED AUDIENCE
Primary care physicians, nurse practitioners, and physician assistants who provide care for patients with migraine
ACCREDITATION STATEMENT

In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The AAFP has reviewed UNMET NEEDS AND THE EVOLVING LANDSCAPE IN ACUTE TREATMENT OF MIGRAINE: Primary Care Professionals on the Front Line, and deemed it acceptable for AAFP credit. Term of approval is from 09/25/2020 to 6/30/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit approval includes the following session(s):

- Getting Back on Track: Catching up on Care During COVID – April 17, 2021

CREDIT DESIGNATION STATEMENT

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

FOR PHYSICIANS:

Haymarket Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA/AAFP EQUIVALENCY:

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

DISCLOSURE POLICY AND RESOLUTION OF CONFLICTS OF INTEREST STATEMENT

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

ACCREDITED PROVIDER DISCLOSURE

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
FACULTY DISCLOSURES

The faculty reported the following financial relationships or relationships to products or devices they have with commercial interests related to the content of this CME activity:


She is also on the speakers' bureaus for Allergan, Inc., Amgen Inc., electroCore Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Supernus Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.


OFF-LABEL DISCLOSURE AND DISCLAIMER

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Allergan. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
FACULTY BIOGRAPHIES

**Susan Hutchinson, MD,** is board certified in family medicine and has a subspecialty in headache. She is the founder and Director of the Orange County Migraine & Headache Center in Irvine, California, and is also a volunteer faculty member in the Department of Family Medicine at UC-Irvine Medical Center. Dr. Hutchinson concentrates on the management of migraine and mood disorders, with a special interest in the relationship of both conditions to hormones. She is a national speaker on both migraine and depression and was awarded the National Headache Foundation Lectureship Award in February 2003 in recognition of her contribution to headache education. In addition, Dr. Hutchinson was selected as a Physician of Excellence by the Orange County Medical Association in January 2007 and is a past President of the Orange County Chapter of the California Academy of Family Physicians. She also served as Chair of the Women’s Issues Section of American Headache Society from 2005 to 2010 and is currently President of the Headache Cooperative of the Pacific. In recent years, Dr. Hutchinson has coauthored numerous journal articles and chapters on the subject of migraine and, in 2013, she wrote and published her first book to be used as a resource for female migraine sufferers.

**Stewart J. Tepper, MD, FAHS,** is a Professor of Neurology at the Geisel School of Medicine at Dartmouth College in Hanover, New Hampshire, and the Director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr. Tepper received his undergraduate degree in the study of the nervous system/psychobiology from Yale College in New Haven, Connecticut, and attended Cornell University Medical College in New York City. He completed his neurology residency at Harvard Medical School in Boston, Massachusetts, and has been board certified in headache medicine since 2006.

Dr. Tepper is Director of the Scottsdale Headache Symposium CME course of the American Headache Society (AHS), a role he has held since 2008. Further, he is the Corporate Liaison and serves on the Board of Directors for the AHS, and he also sits on the Board of Directors of the American Migraine Foundation. In addition, Dr. Tepper is Editor-in-Chief of the journal *Headache Currents* and Associate Editor for the journal *Headache*. To date, he has published more than 430 peer-reviewed manuscripts, editorials, and books on headache medicine.